Article Figures & Data
Tables
- Table 1.
Characteristics of participants of the HPFS by aspirin use at baseline, standardized to the age distribution of the study population
Baseline characteristics, 1986 Nonusers of aspirin Current users of aspirin N 34,848 14,547 Frequency of aspirin use, mean (SD; d/mo) 0.0 8.6 (0.0)a Age, mean (SD; y)b 53.7 (9.7) 56.5 (9.7) BMI, mean (SD; kg/m2) 25.5 (3.3) 25.7 (3.5) Family history of prostate cancer 12.0% 11.8% Smoking status Never smoker 45.7% 41.8% Past smoker 39.6% 47.3% Current smoker 9.3% 10.4% Missing 5.4% 0.5% Total physical activity, mean (SD; METS-h/wk) 18.8 (26.5) 18.6 (26.1) Diabetes diagnosis 3.0% 3.6% Cumulative incidence, by 2009 Prostate cancer diagnosis 12.5% 12.7% Prostate cancer death 1.3% 1.1% Overall mortality 27.7% 30.8% - Table 2.
ERG-positive and ERG-negative incident prostate cancer by aspirin use (fully adjusted modela)
No. of cases HR (95% CI) ERG-positive ERG-negative Total 439 473 ERG-positive ERG-negative Categories of use Never user 147 138 1 (ref) 1 (ref) Past user 107 114 1.02 (0.79–1.31) 1.04 (0.82–1.33) Current user 185 221 1.03 (0.83–1.28) 1.11 (0.89–1.37) Pheterogeneity = 0.88 Current use Never/past user 254 252 1 (ref) 1 (ref) Current user 185 221 1.02 (0.85–1.23) 1.09 (0.91–1.30) Pheterogeneity = 0.63 Ever use Never user 147 138 1 (ref) 1 (ref) Ever user 292 335 1.03 (0.84–1.25) 1.08 (0.89–1.33) Pheterogeneity = 0.69 Duration of use since baseline Non-aspirin user 147 138 1 (ref) 1 (ref) Aspirin use <5 years 134 149 1.00 (0.79–1.26) 1.17 (0.94–1.46) Aspirin use 5–<10 years 90 92 1.11 (0.85–1.44) 0.98 (0.76–1.28) Aspirin use 10 years+ 68 94 0.96 (0.71–1.30) 1.03 (0.77–1.37) Pheterogeneity = 0.48 Per year of use 439 473 1.00 (1.00–1.00) 1.00 (1.00–1.00) Pheterogeneity = 0.62 Frequency of use Aspirin use <2 d/wk (never/past user) 254 252 1 (ref) 1 (ref) Aspirin use 2–<6 d/wk 72 81 0.94 (0.73–1.21) 1.05 (0.83–1.33) Aspirin use 6+ d/wk 113 140 1.09 (0.87–1.37) 1.12 (0.90–1.39) Pheterogeneity = 0.82 Per d/wk of use 439 473 1.02 (0.98–1.05) 1.01 (0.98–1.05) Pheterogeneity = 0.93 Abbreviation: ref, reference category.
↵aAdjusted for age, calendar time, race (Caucasian, other), family history of prostate cancer in father or brother (yes, no), height (≤68, >68–70, >70–72, >72 inches), body mass index (<21, 21–<25, 25–<30, 30+ kg/m2), body mass index at age 21 years (<20, 21–<25, 25–<30, 30+ kg/m2), physical activity (quintiles of metabolic equivalents-hours/week), smoking (never, former/quit >10 years ago, former/quit ≤10 years ago, current), history of diabetes (yes, no), time-varying current statin use (yes, no), PSA testing in the 2 years prior to the questionnaire date (yes, no; lagged by one period to avoid counting diagnostic PSA tests as screening), and PSA testing in >50% of possible time periods (yes, no; lagged by one period to avoid counting diagnostic PSA tests as screening).